Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Yet, other parameters did not differ among groups (Table 2).The biochemical profiles of the study and reference groups.ParameterUnitStudy group (n = 56)Reference group (n = 24)P-valueMedian (range)Median (range)CHOLmg/dL231194.50.029(162 to 363)(101 to 282)LDLmg/dL160.5117.4 < 0.001(88 to 314)(55.7 to 192)TGmg/dL139.3127.50.921(40 to 411)(45 to 211)HDLmg/dL50.4759.210.043(31 to 90)(37 to 114)GLUCOSEmg/dL96.0596.440.508(77 to 154)(69 to 248)CRPmg/L2.153.40.587(0.4 to 8.8)(0.2 to 32.6)25-OH VIT Dng/ml27.2827.190.597(10.6 to 51.1)(8.2 to 82.6)TGBng/ml4.41.30.054(0.04 to 37.05)(0.04 to 3.2)TGBAbIU/mL11.228.990.713(0.6 to 132.4)(0 to 185)TSHμIU/mL0.764.380.092(0.05 to 3.83)(0.09 to 7.3)FT3pg/mL2.642.640.883(1.36 to 3.76)(1.0 to 6.27)FT4ng/dL1.21.180.941(0.54 to 2.14)(0.4 to 1.82)Bold indicates that the values given are statistically significant.CHOL, cholesterol; CRP, C-reactive protein; PTC, papillary thyroid cancer; fT3, free triiodothyronine; fT4, free thyroxine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TGB, thyroglobulin; TGBAb, antithyroglobulin antibodies; TSH, thyroid-stimulating hormone; VIT D, vitamin D.
Source: Biochemical characterization. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
All patients were diagnosed as having PTC based on clinical laboratory tests and ultrasound imaging, then confirmed by fine needle aspiration biopsy (FNAB), followed by histopathological examination.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer
Study design awaiting verification · Scientific Reports · 2023
Original publication title
Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Angioinvasion remains the important prognostic feature in papillary thyroid cancer (PTC) patients. Literature data indicates several markers that may be associated with oxidative stress and/or angioinvasion. Therefore, we assessed the utility of selected parameters in angioinvasion and metastasis screening in serum of PTC patients. Serum antioxidant capacity (TAC) and sirtuin 3 (SIRT3) levels were decreased (all p < 0.05) and both DNA/RNA oxidative stress damage products (DNA/RNA OSDP) and malondialdehyde (MDA) levels were increased in PTC patients with angioinvasion and metastasis (study group) when compared with PTC patients without these features (all p < 0.01).
The highest screening utility in differentiation between angioinvasion and metastasis presence and absence in PTC patients was presented for DNA/RNA OSDP (AUC = 0.71), SIRT3 (AUC = 0.70), and TAC (AUC = 0.67) (all p < 0.05). Our study suggests that peripheral concentration of oxidative stress markers could be useful as angioinvasion and metastasis indicator in PTC patients.
Authors’ abstract
Angioinvasion remains the important prognostic feature in papillary thyroid cancer (PTC) patients. Literature data indicates several markers that may be associated with oxidative stress and/or angioinvasion. Therefore, we assessed the utility of selected parameters in angioinvasion and metastasis screening in serum of PTC patients. Serum antioxidant capacity (TAC) and sirtuin 3 (SIRT3) levels were decreased (all p < 0.05) and both DNA/RNA oxidative stress damage products (DNA/RNA OSDP) and malondialdehyde (MDA) levels were increased in PTC patients with angioinvasion and metastasis (study group) when compared with PTC patients without these features (all p < 0.01).
The highest screening utility in differentiation between angioinvasion and metastasis presence and absence in PTC patients was presented for DNA/RNA OSDP (AUC = 0.71), SIRT3 (AUC = 0.70), and TAC (AUC = 0.67) (all p < 0.05). Our study suggests that peripheral concentration of oxidative stress markers could be useful as angioinvasion and metastasis indicator in PTC patients.
Publication and source details
Original title: Clinical significance of oxidative stress markers as angioinvasion and metastasis indicators in papillary thyroid cancer
Angelika Buczyńska; Iwona Sidorkiewicz; Maria Kościuszko; Agnieszka Adamska; Katarzyna Siewko; Janusz Dzięcioł; Piotr Szumowski; Janusz Myśliwiec; Małgorzata Szelachowska; Anna Popławska-Kita; Adam Krętowski
Scientific Reports · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.internal financing of Medical University of BialystokSUB/1/DN/22/002/1150Popławska-Kita AnnaRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T16:46:18.979861+00:00
DOI: 10.1038/s41598-023-40898-9 · PMC10444813